Navigation Links
MAP Pharmaceuticals Reports 2007 Fourth Quarter and Year End Financial Results
Date:2/28/2008

MAP0004 demonstrated pain relief in 32% of patients at ten minutes,

pain relief in 72% of patients at two hours, and sustained pain relief

in 43% of patients at 24 hours in a treatment received population.

The trial also showed clinically significant trends in the resolution

of phonophobia, photophobia and nausea at certain time points.

MAP0004 was shown in the trial to be well tolerated and no serious

adverse events were reported.

-- Conducted end of Phase 2 meetings with the U.S. Food and Drug

Administration for UDB and MAP0004 in preparation for the initiation

of Phase 3 clinical programs.

-- Initiated a Phase 2a clinical trial of MAP0005 for the potential

treatment of asthma and chronic obstructive pulmonary disease.

MAP0005 combines a corticosteroid and a long-acting beta-agonist

within a single particle, and is administered via the company's

proprietary Tempo(TM) inhaler.

-- Added experienced pharmaceutical industry executives to its management

team and board of directors. Charlene A. Friedman was appointed Vice

President, General Counsel and Secretary, and Shashidar Kori, M.D. was

appointed Vice President of Clinical Development. Also, Bernard J.

Kelley, former President, Merck Manufacturing Division, Merck & Co.,

Inc., was appointed to the board of directors.

-- Completed its initial public offering and a Series D equity financing,

raising combined gross proceeds of approximately $119 million to

further support research and development.

"In 2007, positive results in two Phase 2 programs allowed us to focus our resources on planning for the advancement of our pediatric asthma and migraine drug candidates into late-stage clinical trials," said Timothy S. Nelson, President and Chief Executive Officer of MAP Pharmaceuticals.
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/26/2014)... Angeles, CA (PRWEB) December 26, 2014 ... power score of 3.1 out of 5. This score ... a low level of product specialization, low switching costs ... power is reduced by the low availability of substitutes ... the world price of steel and aluminum, key inputs ...
(Date:12/26/2014)... 2014 “Many people become overwhelmed by ... claim issues and phone calls with insurance companies,” The ... featuring their free eBook on pedestrian and bicycle ... pedestrian and bicycle auto accident claims assures the injured ... of professionally handling their case while they focus on ...
(Date:12/26/2014)... Phoenix, AZ (PRWEB) December 26, 2014 ... dependable source for the best in heating, cooling ... demand for 24 hour emergency services in 2014 ... customers alike know that Arizona is known for ... contractor company that understands the intricacies and details ...
(Date:12/25/2014)... The report “Nintedanib (Colorectal Cancer) – ... the current treatment landscape, unmet needs, current pipeline ... Stivarga is a drug which is used in ... Ingelheim is developing nintedanib (BIBF-1120), an orally available ... in the US, Europe, and Japan. The drug ...
(Date:12/25/2014)... Recently, iFitDress.com, the popular online supplier of ... its new selection of black one-shoulder cocktail dresses . ... they are available at discounted prices, up to 70% off. ... last for three weeks only. You know, we have thousands ... interested in our new items can visit our website for ...
Breaking Medicine News(10 mins):Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 3Health News:Guide to Handling Pedestrian and Bicycle Accidents Released By The Jones Firm, Featured in Recent Article 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2
... N.J., Dec. 3 Covance Inc. (NYSE:,CVD), a ... leading,humanitarian organization, announced today that they are partnering ... for,Orphans and Vulnerable Children in Rwanda. Covance will ... day care centers for,children ages two to four ...
... protect cells from the powerful, common chemotherapeutic agent doxorubicin ... the drug also can destroy the heart., We found ... cell survival in the face of doxorubicin, says Dr. ... Georgia Cancer Center. At the moment you start inactivating ...
... debate , MONDAY, Dec. 3 (HealthDay News) -- There,s ... the risk of developing multiple sclerosis (MS) in childhood, a ... investigated a possible association between the hepatitis B vaccine and ... short- or long-term risk of MS. However, the studies ...
... HARBOR, N.Y. (Mon., Dec. 3, 2007) Two ... early embryogenesis are featured in this months release of ... which are freely accessible online ( www.cshprotocols.org ), describe ... These cell-tagging techniques, combined with sophisticated imaging methods, ...
... As momentum continues to,build on the issue of ... the Pharmaceutical Care Management Association,(PCMA) today announced a ... Ph.D., Sc.D., Last year, Dr. Bootman co-chaired ... all physicians begin using e-prescribing by,2010 to help ...
... and HUNTSVILLE, Ala., Dec. 3 Operon,Biotechnologies, Eurofins ... the,Eurofins Genomics network - announced today that they ... a new worldwide leader in the competitive,custom oligonucleotide ... state of,the art high-throughput production facilities in all ...
Cached Medicine News:Health News:Covance and Care Partner on Rwanda Early Childhood Development Initiative 2Health News:Covance and Care Partner on Rwanda Early Childhood Development Initiative 3Health News:Genes identified that protect against heart damage from chemotherapy 2Health News:No Link Between Hepatitis B Shot, MS: Study 2Health News:Cold Spring Harbor Protocols features innovative methods for embryology research 2Health News:MWG and Operon Are Joining Forces 2
(Date:12/24/2014)... BEIJING , Dec. 24, 2014  The International Trade ... by ResMed (RMD) against BMC Medical. In a notice issued ... and found that ResMed,s patent on its humidifier was invalid. ... decision a "monumental win". "We are very excited with the ... the position that we have taken since the very beginning ...
(Date:12/24/2014)... LONDON , December 24, 2014 /PRNewswire/ ... expected to grow at an average rate of 8.1%. ... and volume. Hip, knee and spine surgeries are the ... emerging economies they have a lower penetration. Increased number ... use of composites. Non-metallic orthopedic devices have gained popularity ...
(Date:12/24/2014)... ResMed (NYSE: RMD ) today announced ... medical device manufacturer BMC Medical Co., Ltd. ... listed below infringe ResMed,s patents, and entered an order prohibiting ... the United States : , iVolve ... Willow nasal pillows mask , iVolve full face mask ...
Breaking Medicine Technology:ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2
... VIEW, Calif., Sept. 16 Based on its recent ... market, Frost & Sullivan recognizes Accelrys, Inc., with the ... Product Innovation of the Year. The company has merited ... a solution that provides, for the first time, a ...
... (LIG) (Pink Sheets: LIGA ), a Dallas-based ... cleaner and disinfectant for the masks of CPAP (continuous ... for patients suffering from sleep apnea. The ... by Jones Products Company, LLC, which is 51% owned ...
Cached Medicine Technology:Frost & Sullivan Acknowledges Accelrys for Scientific Informatics Solution 2Frost & Sullivan Acknowledges Accelrys for Scientific Informatics Solution 3Frost & Sullivan Acknowledges Accelrys for Scientific Informatics Solution 4LIG Assets, Inc. Begins Distribution and Marketing of Unique CPAP Mask Cleaner 2LIG Assets, Inc. Begins Distribution and Marketing of Unique CPAP Mask Cleaner 3
... new Finnpipette Focus from Thermo ... combine ergonomics with uncompromising performance. ... plate offers a custom fit ... new shorter tip cones allow ...
... The Eppendorf Reference Series 2000 Pipette is ... stroke, a compact and robust design, and ... is used to operate the measuring stroke ... tip. Product features:Eppendorf "pipette/tip" system ensures utmost ...
Inquire...
... precision, ergonomics, and value!, Comfortable ... soft non-slip, contoured handle , Finer ... plunger spring action , Completely autoclavable ... the need for recalibration , Easy-to-read ...
Medicine Products: